The North America opioid market is expected to reach USD 18.5 billion by 2024, according to a new report by Grand View Research, Inc. Favorable regulations and healthcare reforms are providing an environment, conducive for research and development as well as commercialization efforts directed toward the development of novel abuse-deterrent opioids, to flourish and drive the industry growth during the forecast period. Furthermore, the key players are deploying large funds in the development of abuse-deterrent technology wherein drugs are designed to be tamper resistant. This is achieved through alterations involving, among others, the use of physical or chemical barriers to resist convenient extraction of the opioids, the addition of an aversive agent to the formulation that would yield an unpleasant effect upon its extraction, and the formulation of opioid prodrugs that are dependent on enzymatic activity in order to be rendered to their active forms. These tamper-resistant opioid drug forms are anticipated to mitigate the incidence of their misuse.
Opioids are the mainstay of chronic pain management that is used to alleviate varied pain conditions. Opiates including codeine and morphine are frequently employed as cough suppression medication. Codeine is considered as a gold standard for cough suppression since it has minimal side effects. Moreover, these narcoticsare used in the treatment of irritable bowel syndrome-induced diarrhea since they act on gastrointestinal receptors. In addition, peripherally acting loperamide is commonly used to suppress diarrhea. Thus, theprofitable growth of the Opioid Market lies in its breadth of applications in the management of diverse conditions including cough, diarrhea, and pain.
View
summary of this report @ http://www.grandviewresearch.com/industry-analysis/north-america-opioid-market
Further key findings from the study suggest:
·
The extended-release opioids segment accounted
for the largest share over 55% in 2015. The dominance of the segment is
attributed to the high usage of these drugs for chronic pain management and the
development of innovative dosage forms, such as transdermal patches.
·
Market share of the immediate-release dosage
formsincluding morphine and codeine, is expected to decline owing to the
frequent product recalls and severe side effects associated with their use. The
segment is estimated to witness a CAGR of around 1.7% over the forecast period.
·
In terms of applications, the pain relief
segment held the largest market share in 2015 with a revenue generation of over
9.3 billion. The extensive amount of pain caused during chemotherapy and
radiotherapy are the primary factors resulting in the increasing incorporation
of these drugs in the cancer segment.
·
The post-operative pain management segment is
expected to be the fastest growing application in the pain relief category.As a
result of their high applicability in post- surgical pain management, the rise
in number of surgical procedures is expected to fuel the sectorpenetration of
opioids in the near future.
·
The U.S. region dominated the global Opioid
Market with a sizable revenue share in 2015. One of the major determinants is
the growing geriatric population with clinically demonstrated susceptibility to
terminal conditions, such as rheumatoid arthritis, is positively impacting this
vertical.
·
In addition, the increasing adoption of opioids
for pain management related to trauma and injury cases, in severe and chronic
disabling diseases, and in cases of post-surgical pain, is driving the growth
of the market in the North America region
·
The Canada regional verticalis expected to
witnesssignificant growth over the forecast period with a CAGR of over 5.3% due
tothe improvinghealthcare infrastructure and the presence of favorable
government reforms governing the use of narcoticsin the treatment of both,
acute and chronic pain, as well as in the cases of persistent cough and diarrhea.
Additionally, the expanding generic drugs market in this region is expected to
provide a potential growth platform for the key players in this vertical.
·
Some of the leadingplayers in this
verticalinclude Pfizer, Inc., Purdue Pharma L.P., Janssen Pharmaceuticals,
Inc., Allergan Plc (Actavis), and Egalet Corporation. Extensive research and
development endeavors carried out by companies with the aim of expanding their
product pipeline are expected to boost the growth of this sector.
Browse
more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the North America opioids market on the basis of product, application,and region:
North America Opioid Market, product outlook by revenue (USD Million, 2014 - 2024)
·
Immediate - release / Short - acting Opioids
·
Codeine
·
Oxycodone
·
Hydrocodone
·
Fentanyl
·
Morphine
·
Hydroxymorphone
·
Oxymorphone
·
Propoxyphene
·
Other IR opioids
·
Extended - release / Long - acting Opioids
·
Oxycodone
·
Hydrocodone
·
Methadone
·
Fentanyl
·
Morphine
·
Oxymorphone
·
Tapentadol
·
Buprenorphine
·
Hydromorphone
·
Other ER opioids
North America Opioid Market, application outlook by revenue (USD
Million, 2014 - 2024)
·
Pain Relief
o
Cancer Pain
o
Post-operative Pain Management
o
Low Back Pain
o
Orthopedic
o
Neuropathic Pain
o
Fibromyalgia
·
Anesthesia
·
Cough Suppression
·
Diarrhea suppression
·
De - addiction
North America market, regional outlook by revenue (USD Million, 2014
- 2024)
·
U.S.
For press release of this report - http://www.grandviewresearch.com/press-release/north-america-opioid-market-analysis
About Grand View
Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry
James
Corporate
Sales Specialist, U.S.A.
Grand
View Research, Inc.
United
States
Phone: 1-415-349-0058
Toll
Free: 1-888-202-9519
Email: sales@grandviewresearch.com
No comments:
Post a Comment